Avandia Death Risk Higher Even When Compared with Actos

New data suggests that even when Avandia is compared with Actos, another diabetes drug in the same class of medications, it carries an increased risk of congestive heart failure and death.

Avandia and Actos are both diabetes drugs that are part of the same class of medications, known as thiazolidinedione agents.

A “black box” warning was added to both medications in August 2007 about potential side effects which may increase the risk of congestive heart failure.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Data published this week in The Archives of Internal Medicine suggest that users of Avandia are more likely to experience heart failure or death than users of Actos.

Researchers evaluated data from Medicare claims involving 28,000 diabetics over 65 in Pennsylvania and New jersey. When comparing Actos and Avandia, researchers found that Avandia side effects carried a 13% greater chance of heart failure and a 15% higher rate of death.

Avandia (rosiglitazone), was once a blockbuster diabetes drug, generating over $2 billion in annual sales before a report was published in the New England Journal of Medicine in May 2007 that associated the drug with an increased risk of heart attacks and death.

Since that time, the American Diabetes Association and the European Association for the Study of Diabetes have unanimously advised against use of Avandia due to the heart risks, and the consumer advocacy group Public Citizen has filed a petition with the FDA calling for an Avandia recall.

GlaxoSmithKline, PLC, the maker of Avandia, continues to defend their drug and fight to keep it on the market despite the serious and potentially fatal side effects.

In addition to the increased risk of heart attacks, congestive heart failure and death, studies have also linked Avandia side effects to a risk of liver failure, bone fractures and vision loss known as macular edema.

Glaxo currently faces a number of Avandia lawsuits filed by users who have suffered injuries they allege were caused by the diabetes drug. All federal cases have been consolidated in an MDL in the Eastern District of Pennsylvania, with the first trials scheduled to begin in 2010.

1 Comments

  • Actos Heart Failure Warning Strengthened in Canada : AboutLawsuits.comDecember 22, 2008 at 4:41 pm

    [...] heart failure, a study published last month in The Archives of Internal Medicine suggested that users of Avandia are more likely to experience heart failure or death than users of Actos. When comparing use of the two drugs among 28,000 diabetics over 65, researchers found that Avandia [...]

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

AFFF Ulcerative Colitis Lawsuit Filed Over Contaminated Water in Colorado Springs
AFFF Ulcerative Colitis Lawsuit Filed Over Contaminated Water in Colorado Springs (Posted today)

Lawsuit blames PFAS manufacturers for failing to prevent water contamination by their chemicals, or warn municipalities and the public about the potential risks of ulcerative colitis and other diseases as a result of exposure.

Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria
Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria (Posted yesterday)

Hundreds of currently pending Bard PowerPort lawsuits over infections, fractures and migration injuries were consolidated into a multidistrict litigation (MDL), but now even more claims present similar allegations that the implantable port catheter system has dangerous design defects that were not adequately disclosed by the manufacturer.

Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters
Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters (Posted yesterday)

A recent report suggests that Johnson & Johnson is offering an additional $1.1 billion to settle talcum powder lawsuits, as part of a proposed $9 billion deal that would resolve all ovarian cancer claims as part of a third bankruptcy filing by the manufacturer.